2024-10-07 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report 

**Company Overview:** Amgen Inc. is a leading biotechnology company focused on developing and delivering innovative therapies for serious illnesses. 

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** AMGN has a cumulative return of 78.76% compared to VOO's 133.14%.
* **Relative Performance:** AMGN is currently underperforming VOO, with a negative relative performance of -54.38%. This places AMGN at the 31.65 percentile of its historical performance range against VOO.

**2. Recent Price Movements:**

* **Closing Price:** $319.66
* **5-Day Moving Average:** $319.88
* **20-Day Moving Average:** $327.44
* **60-Day Moving Average:** $328.38

**3. Technical Indicators:**

* **RSI:** 37.08, suggesting the stock is currently in oversold territory.
* **PPO:** -0.43, indicating a potential bearish trend.
* **Delta_Previous_Relative_Divergence:** -13.26, indicating a recent short-term downward trend.
* **Expected Return:** 0.0%, indicating a 5-year expected return on par with VOO. 

**4. Recent Earnings and Outlook:**

* **Latest Earnings:** AMGN reported earnings per share (EPS) of $1.39 and revenue of $8.39 billion on August 07, 2024. 
* **Analyst Expectations:**  While specific analyst expectations for the latest earnings report are unavailable,  AMGN has consistently exceeded earnings estimates in the past. 
* **Earnings Trend:**  Earnings have generally been positive, with a notable dip in the second quarter of 2024. This could potentially be linked to seasonal factors or market conditions. 

**5. News and Recent Issues:**

* **Recent Market Outlook:**  AMGN continues to face challenges in the biopharmaceutical landscape, including pricing pressures and competition. However, its strong portfolio of therapies, including blockbuster drugs like Repatha and Prolia, continues to drive revenue growth.
* **Analyst Opinions:**  AMGN is generally viewed as a stable and reliable company, with a solid dividend record. However, recent underperformance and competitive pressures have caused some analysts to lower their price targets. 
* **Performance Highlights:**  AMGN's strong brand, established market position, and commitment to innovation remain its key strengths. However, the company is facing increased pressure to innovate and develop new therapies to maintain its market leadership.

**6. Overall Analysis:**

* **AMGN's performance has lagged behind the broader market.** Its recent underperformance and bearish technical indicators suggest potential further downside.
* **Despite a strong portfolio of existing therapies, AMGN's future growth depends on innovation and successful product development.** The company's commitment to research and development will be key to its long-term success.
* **While the company is facing challenges, it remains a solid and established player in the biotechnology industry.** Its dividend track record and consistent earnings make it an attractive investment for income-focused investors.

**7. Recommendations:**

* **Investors should closely monitor AMGN's earnings and its ability to compete in the evolving biopharmaceutical landscape.**
* **The stock's recent underperformance and bearish technical indicators suggest a potential for further downside in the short-term.**
* **Long-term investors may consider AMGN as a potential holding for its strong brand and dividend record, but it's important to be aware of the challenges the company faces.**

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. It is essential to conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
